RPL3 and colonic neoplasm: Overall, our findings highlighted AdoMet, a naturally-occurring multifunctional sulfonium compound, as a potential candidate for novel therapeutic approaches to overcome the drug resistance of colon cancer depending on p53 and uL3 status.